Biggest News Aggregation in the World
📰 World Dynamix News

Page 2 - World Dynamix News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from World Dynamix. Real-time updates on events, politics, business and more.

Major Shifts in Management of Patients with Lupus Nephritis Spurred by Availability of Aurinia Pharmaceutical's Lupkynis and GSK's Benlysta, According to Spherix Global Insights

/PRNewswire/ -- With the approvals of GlaxoSmithKlines Benlysta (belimumab) in lupus nephritis (LN) at the end of 2020 and Aurinias Lupkynis (voclosporin) at...
Novarti Cosentyx Astrazeneca Saphnelo Glaxosmithkline Benlysta Scott Upham Roche Genentech Gazyva Aurinia Lupkynis

Switching Patterns Among Neovascular Age-Related Macular Degeneration: Genentech's Vabysmo Rising, Regeneron's Eylea and Genentech's Off-Label Avastin Remain Strong, According to Spherix Global Insights

/PRNewswire/ -- The switch landscape represents an active segment of the market where brands have the opportunity to capture share. Spherixs RealWorld...
Coherus Bioscience Cimerli Genentech Susvimo Scott Upham Genentech Vabysmo Regeneron Eylea Chrystal Ferguson

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Off-Label Avastin (Genentech) Dominates First-Line Biologic Use in Diabetic Retinopathy Despite Eylea's (Regeneron) Best Efforts to Secure Share in the Space, According to Spherix Global Insights

/PRNewswire/ -- Despite the availability of on-label products to treat diabetic retinopathy (DR), Genentechs off-label option, Avastin, is the predominant...
Vabysmo Genentech Genentech Lucentis National Institute Of Health While Eylea Realworld Dynamix Biologic New Starts

Despite Amplified Use of SGLT2 Inhibitors for Glomerular Diseases, EU and US Nephrologists Express a Continued Strong Desire for New Treatment Options for FSGS Patients, Spherix Reports

/PRNewswire/ -- Focal segmental glomerulosclerosis (FSGS) is one of the leading causes of nephrotic syndrome across the world and is considered the most common...
United States United Kingdom Janssen Invokana Sparsentan Travere Astrazeneca Farxiga Forxiga Boehringer Ingelheim Lilly Jardiance

New IBD Mechanisms of Action Are Poised to Gain EU5 Patient Switches as Anti-TNF Therapy Efficacy Fades in Ulcerative Colitis and Crohn's Disease, According to Spherix Global Insights

/PRNewswire/ -- According to the latest report published as part of Spherixs RealWorld Dynamix™: Biologic/Small Molecule Switching in IBD (EU) service, EU...
United Kingdom Abbvie Rinvoq Janssen Stelara Paul Zimmerman Realworld Dynamix Small Molecule Switching

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science